BIOMARIN PHARMACEUTICAL INC (BMRN) Quick Ratio
- Quick ratio · latest quarter: Value 1.16×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 1.16× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $1.94B ÷ $1.66B ≈ 1.16× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 1.94B USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 1.66B USD | Liabilities, Current |
| Cash and equivalents | 874.00M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 0.00 USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 1.06B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 1.78B USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.94B | $1.66B | $874.00M | $0.00 | $1.06B | $1.78B | 1.16× |
| 2026-03-31 | $3.13B | $793.15M | $2.22B | $0.00 | $903.91M | $1.27B | 3.94× |
| 2025-12-31 | $2.47B | $759.03M | $1.31B | $248.93M | $908.21M | $1.30B | 3.25× |
| 2025-09-30 | $2.27B | $798.44M | $1.25B | $227.73M | $790.27M | $1.38B | 2.84× |
| 2025-06-30 | $2.29B | $684.25M | $1.21B | $218.31M | $855.86M | $1.34B | 3.34× |
| 2025-03-31 | $2.01B | $628.21M | $1.05B | $223.53M | $739.18M | $1.27B | 3.20× |
| 2024-12-31 | $1.80B | $606.99M | $942.84M | $194.86M | $660.53M | $1.23B | 2.96× |
| 2024-09-30 | $1.71B | $715.66M | $675.45M | $255.00M | $777.55M | $1.18B | 2.39× |
| 2024-06-30 | $1.92B | $1.07B | $972.15M | $252.20M | $691.23M | $1.18B | 1.79× |
| 2024-03-31 | $1.68B | $1.09B | $747.00M | $299.58M | $637.16M | $1.14B | 1.55× |
| 2023-12-31 | $1.71B | $1.18B | $755.13M | $318.68M | $633.70M | $1.11B | 1.45× |
| 2023-09-30 | $1.70B | $1.16B | $785.41M | $340.43M | $572.50M | $1.03B | 1.46× |
| 2023-06-30 | $1.78B | $597.23M | $694.38M | $476.58M | $610.22M | $975.55M | 2.98× |
| 2023-03-31 | $1.75B | $598.23M | $580.07M | $572.02M | $597.91M | $918.92M | 2.93× |
| 2022-12-31 | $1.75B | $588.88M | $724.53M | $567.01M | $461.32M | $894.08M | 2.98× |
| 2022-09-30 | $1.69B | $521.02M | $761.51M | $512.25M | $419.62M | $839.46M | 3.25× |
| 2022-06-30 | $1.58B | $464.73M | $619.80M | $489.94M | $466.51M | $802.32M | 3.39× |
| 2022-03-31 | $1.49B | $490.42M | $605.44M | $450.80M | $430.15M | $786.36M | 3.03× |
| 2021-12-31 | $1.39B | $539.82M | $587.28M | $426.60M | $373.40M | $776.67M | 2.57× |
| 2021-09-30 | $1.45B | $514.90M | $617.14M | $462.33M | $374.94M | $749.41M | 2.82× |
| 2021-06-30 | $1.55B | $443.34M | $641.53M | $481.86M | $424.42M | $710.98M | 3.49× |
| 2021-03-31 | $1.48B | $430.04M | $667.31M | $420.18M | $396.10M | $713.93M | 3.45× |
| 2020-12-31 | $1.51B | $492.55M | $649.16M | $416.23M | $448.35M | $698.55M | 3.07× |
| 2020-09-30 | $1.92B | $854.69M | $1.02B | $490.00M | $411.71M | $700.85M | 2.24× |
| 2020-06-30 | $1.76B | $813.30M | $818.90M | $561.47M | $381.21M | $743.85M | 2.17× |
| 2020-03-31 | $1.25B | $820.47M | $476.63M | $381.76M | $396.38M | $705.65M | 1.53× |
| 2019-12-31 | $1.13B | $932.50M | $437.45M | $316.36M | $377.40M | $680.27M | 1.21× |
| 2019-09-30 | $1.12B | $493.75M | $423.22M | $297.57M | $402.97M | $609.05M | 2.28× |
| 2019-06-30 | $1.11B | $439.43M | $307.58M | $423.53M | $377.15M | $578.74M | 2.52× |
| 2019-03-31 | $1.29B | $500.99M | $364.37M | $530.49M | $393.43M | $534.70M | 2.57× |
| 2018-12-31 | $1.43B | $523.24M | $493.98M | $590.33M | $342.63M | $530.87M | 2.73× |
| 2018-09-30 | $1.83B | $838.66M | $882.18M | $561.19M | $384.34M | $508.48M | 2.18× |
| 2018-06-30 | $1.73B | $804.95M | $427.41M | $935.66M | $363.57M | $473.36M | 2.15× |
| 2018-03-31 | $1.70B | $773.47M | $473.98M | $908.82M | $318.39M | $468.16M | 2.20× |
| 2017-12-31 | (m) | $816.52M | $598.03M | (m) | $261.37M | $475.77M | (m) |
| 2017-09-30 | (m) | $417.53M | $431.40M | (m) | $251.89M | $457.39M | (m) |
| 2017-06-30 | (m) | $374.30M | $354.86M | (m) | $238.34M | $429.83M | (m) |
| 2017-03-31 | (m) | $340.21M | $348.23M | (m) | $230.25M | $384.14M | (m) |
| 2016-12-31 | (m) | $439.31M | $408.33M | (m) | $215.28M | $355.13M | (m) |
| 2016-09-30 | (m) | $377.33M | $707.35M | (m) | $215.89M | $347.42M | (m) |
| 2016-06-30 | (m) | $364.58M | $305.97M | (m) | $214.16M | $326.56M | (m) |
| 2016-03-31 | (m) | $388.01M | $270.45M | (m) | $180.75M | $296.98M | (m) |
| 2015-12-31 | (m) | $445.46M | $397.04M | (m) | $164.96M | $271.68M | (m) |
| 2015-09-30 | (m) | $390.49M | $376.35M | (m) | $148.95M | $262.10M | (m) |
| 2015-06-30 | (m) | $347.70M | $440.66M | (m) | $186.08M | $237.53M | (m) |
| 2015-03-31 | (m) | $305.51M | $900.57M | (m) | $175.74M | $222.83M | (m) |
| 2014-12-31 | (m) | $235.74M | $875.49M | (m) | $144.47M | $199.45M | (m) |
| 2014-09-30 | (m) | $206.55M | $398.00M | (m) | $121.39M | $204.44M | (m) |
| 2014-06-30 | (m) | $166.72M | $584.72M | (m) | $122.28M | $193.50M | (m) |
| 2014-03-31 | (m) | $156.04M | $639.78M | (m) | $110.46M | $176.89M | (m) |
| 2013-12-31 | (m) | $183.27M | $568.78M | (m) | $117.82M | $162.60M | (m) |
| 2013-09-30 | (m) | $167.63M | $181.56M | (m) | $124.75M | $148.68M | (m) |
| 2013-06-30 | (m) | $142.24M | $175.44M | (m) | $115.06M | $142.30M | (m) |
| 2013-03-31 | (m) | $144.01M | $154.38M | (m) | $120.34M | $135.82M | (m) |
| 2012-12-31 | (m) | $170.43M | $180.53M | (m) | $109.07M | $128.69M | (m) |
| 2012-09-30 | (m) | $134.93M | $181.33M | (m) | $117.29M | $120.83M | (m) |
| 2012-06-30 | (m) | $120.00M | $177.76M | (m) | $100.75M | $120.13M | (m) |
| 2012-03-31 | (m) | $119.81M | $82.59M | (m) | $105.83M | $124.06M | (m) |
| 2011-12-31 | (m) | $94.13M | $46.27M | (m) | $104.84M | $130.12M | (m) |
| 2011-09-30 | (m) | $83.25M | $71.25M | (m) | $107.06M | $115.63M | (m) |
| 2011-06-30 | (m) | $82.03M | $112.96M | (m) | $106.61M | $112.30M | (m) |
| 2011-03-31 | (m) | $75.99M | $90.78M | (m) | $106.20M | $110.07M | (m) |
| 2010-12-31 | (m) | $83.84M | $88.08M | (m) | $86.58M | $109.70M | (m) |
| 2010-09-30 | (m) | $92.10M | $127.54M | (m) | $78.73M | $91.74M | (m) |
| 2010-06-30 | (m) | $83.93M | $115.78M | (m) | $77.68M | $83.78M | (m) |
| 2010-03-31 | (m) | (m) | $108.96M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $78.15M | $167.17M | (m) | $73.54M | $78.66M | (m) |
| 2009-09-30 | (m) | (m) | $191.78M | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | $200.05M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $222.90M | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | $228.34M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |